Biopharmaceutical company BerGenBio ASA (OSE:BGBIO) reported on Monday the start of treatment of the first hospitalised COVID-19 patient with bemcentinib at the University Hospital Southampton NHS Foundation Trust in the UK Government-backed Phase II clinical trial.
On 28th April 2020, Bemcentinib was selected as the first candidate to be tested under the fully funded ACcelerating COVID-19 Research & Development platform (ACCORD) study and the Department of Health and Social Care (DHSC) and UK Research and Innovation (UKRI). The drug material and other trial resources will be provided by BerGenBio.
The company added that the Phase II study is open in additional seven sites across the UK. The study will recruit 120 subjects to assess the safety and efficacy of bemcentinib as an add-on therapy to standard of care (SoC) in 60 hospitalised COVID-19 patients, with another 60 control group patients receiving SoC.
Top line data is expected in summer and if positive, bemcentinib will advance rapidly into the large-scale Phase III trials in the UK.
ACCORD brings together a single, UK-wide clinical trial platform to rapidly test potential drugs through early stage clinical trials and feed them into the UK's large-scale COVID-19 studies, concluded the company.
TiumBio files Clinical Trial Application to start Phase 1b TU7710 study
Moderna reports positive interim results from next-generation COVID-19 vaccine trial
Scancell initiates SCOPE trial's iSCIB1+ cohort
Valneva launches Phase 1 trial for next-generation Zika vaccine
argenx obtains VYVGART approval for primary immune thrombocytopenia in Japan
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval